Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC
Bullboard Posts
User Avatar Image
(0)
•••
Post by toothpickon Mar 25, 2010 3:25pm
624 Views
Post# 16924837

Biologics = 12 years protection

Biologics = 12 years protection

According to...

US healthcare shaken up


https://www.investorschronicle.co.uk/MarketsAndSectors/Sectors/article/20100324/3e4c4858-3749-11df-9d0f-0015171400aa/US-healthcare-shaken-up.jsp


Biologic would get 12 marketing exclusivity - they asked for 14 - while regular drugs got 5 years protection -

"On the other hand, the pharma industry seems to have pulled off a quiet coup by winning a concession in the bill that gives biological medicines up to 12 years of marketing exclusivity (the industry had asked for 14), compared with five years for small-molecule drugs. While biological medicines are difficult to copy, it means generics companies will now have to wait longer before they can launch so-called "biosimilars," the generic equivalents of biological drugs that have their own regulatory approval process."

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities